Provided by Tiger Trade Technology Pte. Ltd.

Vertex Pharmaceuticals

541.66
-0.0300-0.01%
Volume:188.65K
Turnover:101.51M
Market Cap:137.43B
PE:31.52
High:542.34
Open:535.38
Low:532.23
Close:541.69
52wk High:555.69
52wk Low:374.17
Shares:253.72M
Float Shares:253.72M
Volume Ratio:0.35
T/O Rate:0.07%
Dividend:- -
Dividend Rate:- -
EPS(TTM):17.18
EPS(LYR):15.32
ROE:23.54%
ROA:11.93%
PB:6.79
PE(LYR):35.36

Loading ...

Abcellera Announces Collaboration with Vertex to Discover Multispecific T-Cell Engagers for Autoimmune Diseases and Other Conditions

THOMSON REUTERS
·
Jul 29

Abcellera Biologics - Vertex to Fund All R&D and Commercialize Antibodies from Collaboration

THOMSON REUTERS
·
Jul 29

Abcellera Biologics - Abccellera to Receive $28 Mln Upfront Plus Milestone Payments and Tiered Royalties

THOMSON REUTERS
·
Jul 29

Vertex Pharmaceuticals Inc. Stock Underperforms Tuesday When Compared to Competitors Despite Daily Gains

Dow Jones
·
Jul 29

Analysts Conflicted on These Healthcare Names: BioMarin Pharmaceutical (BMRN), Zoetis (ZTS) and Vertex Pharmaceuticals (VRTX)

TIPRANKS
·
Jul 28

Crinetics downgraded to Neutral from Buy at UBS

TIPRANKS
·
Jul 28

Earning Preview: Vertex Pharmaceuticals this quarter’s revenue is expected to increase by 11.23%, and institutional views are bullish

Earnings Agent
·
Jul 27

Vertex Minerals appoints independent expert after multiple ASX Listing Rule breaches

TIPRANKS
·
Jul 23

Vertex Pharmaceuticals Inc. Stock Underperforms Wednesday When Compared to Competitors

Dow Jones
·
Jul 23

What the $10B Crinetics Deal & $2.9B Soleno Acquisition Might Say About Palatin’s Rare-Obesity Opportunity

TIPRANKS
·
Jul 22

Vertex Facing Uncertain Growth Path Amid AI Fears, Morgan Stanley Says

MT Newswires Live
·
Jul 21

Morgan Stanley Downgrades Vertex to Equalweight From Overweight, Cuts Price Target to $15 From $19

MT Newswires Live
·
Jul 21

Vertex Pharmaceuticals Inc. Stock Underperforms Monday When Compared to Competitors

Dow Jones
·
Jul 21

Goldman Sachs Adjusts Price Target on Vertex Pharmaceuticals to $652 From $641, Maintains Buy Rating

MT Newswires Live
·
Jul 20

Vertex Pharmaceuticals Inc. Stock Underperforms Thursday When Compared to Competitors Despite Daily Gains

Dow Jones
·
Jul 17

Vertex’s VX-581 Dose Escalation Trial: A Fresh Signal on Cystic Fibrosis Pipeline Strength

TIPRANKS
·
Jul 17

Vertex Pharmaceuticals BDR Program Executes 8-for-1 Stock Split in Brazil on July 27

Reuters
·
Jul 16

Vertex Pharmaceuticals Currently Down Seven Consecutive Days, on Pace for Longest Losing Streak Since August 2021

Dow Jones
·
Jul 15

After Crinetics’ $10 Billion Deal, Could Entera Bio Be the Next Category-Defining Oral Peptide Story?

TIPRANKS
·
Jul 15

Crinetics Pharmaceuticals (CRNX) Looks Fully Valued As Vertex Agrees $85 Per Share Deal

Simply Wall St.
·
Jul 15